Major Depression Clinical Trial
Official title:
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
The purpose of this research study is to find out if the medication known as ketamine can help the symptoms of depression. This drug is approved by the Food and Drug Administration (FDA) but the investigators will use it for a non-FDA approved reason (depression).
The investigators will enroll 100 adults with treatment-resistant unipolar or bipolar major depression (TRD) across 7 clinical sites and provide three IV ketamine infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers). The investigators will begin by studying the predictive value of mechanistic target of rapamycin (mTOR) target engagement by ketamine using a white blood cell (WBC) assay for antidepressive response to ketamine (Aim 1); however, samples will be used to develop multiple blood-based biomarkers for ketamine antidepressive effects (Aim 2). The investigators will also examine the effect of combining multiple blood-based biomarkers for predicting antidepressive response to ketamine in adults with TRD (Aim 3). Baseline WBC markers of impaired cellular energy regulation will be associated with measures of clinical response to ketamine (predictive biomarker). Changes in WBC markers of impaired cellular energy regulation will be associated with clinical response to ketamine (change biomarker). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
| Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
| Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
| Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
| Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
| Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
| Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
| Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
| Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
| Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
| Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
| Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
| Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
| Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
| Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
| Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
| Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
| Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
| Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
| Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 |